Login to Your Account



Financings Roundup

Ahead of Solzira Resubmission, XenoPort Adds $40M in Offering

By Jennifer Boggs


Wednesday, December 31, 2008
XenoPort Inc., which missed out on an anticipated $23 million milestone payment this quarter after partner GlaxoSmithKline plc yanked the new drug application for Solzira in restless legs syndrome (RLS) due to a filing glitch, beefed up its balance sheet with a $40 million registered direct offering. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription